Showing results (141-150 of 261) with videos related to
Sort By:
Pageof 27
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.Scientific Reports|September 15, 2018
Low survival of strongly footed pheasants may explain constraints on lateralizationMark A Whiteside, Mackenzie M Bess, Elisa Frasnelli, et al.The British Journal of Dermatology|February 22, 2011
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studiesK Reich, R G Langley, M Lebwohl, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2012
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasisR G Langley, K Papp, A B Gottlieb, et al.Lancet (London, England)|January 26, 1980
Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failureA E Gimson, P G Langley, R D Hughes, et al.Journal of the American Academy of Dermatology|March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label studyBruce E Strober, Yves Poulin, Francisco A Kerdel, et al.The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.Journal of the American Academy of Dermatology|July 13, 2010
Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trialRichard G Langley, Amy S Paller, Adelaide A Hebert, et al.Journal of the American Academy of Dermatology|November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisAndrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 20, 2015
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisR G Langley, P Rich, A Menter, et al.Pageof 27